FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the pharmaceutical industry and is a high potency pharmaceutical composition containing a reduced dosage form of particles, including highly active pancreatin, wherein said pancreatin has a specific lipase activity of at least 120 USP (US Pharmacopeia) IU/mg and is present in a dose of 100–110 mg of active pharmaceutical ingredient (API) per dosage amount. Invention also includes a method for producing highly active pancreatin and a method for treating a patient exposed to a physiological condition associated with a deficiency of pancreatic enzymes, through the use of said high potency pharmaceutical composition.
EFFECT: group of inventions allows to obtain pancreatin with lipase activity of at least 120 IU/mg, for which the dose is 100–110 mg per dosage form, which allows to reduce the biological load.
42 cl, 21 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIGESTIVE ENZYME COMPOSITION SUITABLE FOR ENTERAL ADMINISTRATION | 2014 |
|
RU2679832C2 |
| METHOD FOR DISSOLUTION TESTING OF SOLID COMPOSITIONS CONTAINING DIGESTIVE ENZYMES | 2012 |
|
RU2602183C2 |
| STABLE COMPOSITIONS OF DIGESTIVE ENZYMES | 2008 |
|
RU2445952C2 |
| COMPOSITIONS OF PANCREATIC ENZYMES AND METHOD OF TREATING PANCREATITIS AND PANCREAS INSUFFICIENCY | 2010 |
|
RU2570376C2 |
| COMPOSITION CONTAINING DIGESTIVE ENZYMES AND NUTRIENTS SUITABLE FOR ENTERAL ADMINISTRATION | 2014 |
|
RU2651458C2 |
| CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS UNSTABLE IN MEDICINAL ACID MEDIUM | 2006 |
|
RU2440101C2 |
| COMPOSITIONS CONTAINING LIPASE, PROTEASE AND AMYLASE INTENDED FOR TREATMENT OF PANCREATIC INSUFFICIENCY | 2005 |
|
RU2385736C2 |
| PROTEASES FOR PHARMACEUTICAL APPLICATION | 2006 |
|
RU2420578C2 |
| PANCREATINE MICROPELLET NUCLEI TO BE ENTERO-SOLUBLE COATED | 2006 |
|
RU2408364C2 |
| ENZYMES FOR PHARMACEUTICAL APPLICATION | 2005 |
|
RU2389504C2 |
